CAGR of 6.8% forecast for global viral infections market to 2021

The global viral infections market will grow from $74 billion in 2014 to $117.6 billion by 2021, representing a compound annual growth rate of 6.8%, new forecasts suggest.

According to business intelligence provider GBI Research’s latest report, the expanding treatment population, which has resulted from improved treatment options and global initiatives to improve access to treatment for many people living with chronic debilitating viral infections such as HIV, will be a key driver of this growth. Rising therapy costs resulting from the uptake of recently approved, highly-priced antiviral agents, as well as promising late-stage candidates which are expected to be priced highly, will also be a factor.

Fiona Chisholm, an analyst for GBI Research, states: “Some 1,848 pipeline products are specifically in development for the treatment of viral infections, accounting for a sizeable proportion of the infectious diseases pipeline. Among these products, HIV has the most at an active stage of development, with 419, followed by influenza, hepatitis C and hepatitis B, with 333, 222 and 150 pipeline products, respectively.”